Lyra Therapeutics (LYRA)
Market Price (1/17/2026): $1.99 | Market Cap: $3.5 MilSector: Health Care | Industry: Biotechnology
Lyra Therapeutics (LYRA)
Market Price (1/17/2026): $1.99Market Cap: $3.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -49% | Weak multi-year price returns2Y Excs Rtn is -144%, 3Y Excs Rtn is -173% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -32 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5401% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 265% | |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -59%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -23%, Rev Chg QQuarterly Revenue Change % is -87% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 619% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -5691%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5691% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -941% | ||
| High stock price volatilityVol 12M is 4912% | ||
| Key risksLYRA key risks include [1] a dwindling cash reserve and the urgent need for additional capital to fund operations, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -49% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. |
| Weak multi-year price returns2Y Excs Rtn is -144%, 3Y Excs Rtn is -173% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -32 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5401% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 265% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -59%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -23%, Rev Chg QQuarterly Revenue Change % is -87% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 619% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -5691%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5691% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -941% |
| High stock price volatilityVol 12M is 4912% |
| Key risksLYRA key risks include [1] a dwindling cash reserve and the urgent need for additional capital to fund operations, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
1. Suspension of Lead Product Candidate Development: Lyra Therapeutics announced on January 12, 2026, that its Board of Directors approved a plan to suspend further development of LYR-210, its lead product candidate for chronic rhinosinusitis.
2. Workforce Reduction: Concurrent with the suspension of LYR-210, the company implemented a cost reduction plan that included a workforce reduction impacting substantially all of its remaining employees, effective January 12, 2026.
Show more
Stock Movement Drivers
Fundamental Drivers
The -65.5% change in LYRA stock from 10/31/2025 to 1/16/2026 was primarily driven by a -41.9% change in the company's P/S Multiple.| 10312025 | 1162026 | Change | |
|---|---|---|---|
| Stock Price ($) | 5.76 | 1.99 | -65.45% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.77 | 0.60 | -22.08% |
| P/S Multiple | 10.09 | 5.86 | -41.88% |
| Shares Outstanding (Mil) | 1.35 | 1.77 | -31.08% |
| Cumulative Contribution | -68.79% |
Market Drivers
10/31/2025 to 1/16/2026| Return | Correlation | |
|---|---|---|
| LYRA | -65.5% | |
| Market (SPY) | 1.4% | 19.1% |
| Sector (XLV) | 8.0% | -5.0% |
Fundamental Drivers
The -70.3% change in LYRA stock from 7/31/2025 to 1/16/2026 was primarily driven by a -49.4% change in the company's Total Revenues ($ Mil).| 7312025 | 1162026 | Change | |
|---|---|---|---|
| Stock Price ($) | 6.70 | 1.99 | -70.30% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1.19 | 0.60 | -49.37% |
| P/S Multiple | 7.44 | 5.86 | -21.15% |
| Shares Outstanding (Mil) | 1.32 | 1.77 | -34.42% |
| Cumulative Contribution | -73.82% |
Market Drivers
7/31/2025 to 1/16/2026| Return | Correlation | |
|---|---|---|
| LYRA | -70.3% | |
| Market (SPY) | 9.7% | 19.8% |
| Sector (XLV) | 20.0% | 0.9% |
Fundamental Drivers
The -78.2% change in LYRA stock from 1/31/2025 to 1/16/2026 was primarily driven by a -59.2% change in the company's Total Revenues ($ Mil).| 1312025 | 1162026 | Change | |
|---|---|---|---|
| Stock Price ($) | 9.14 | 1.99 | -78.23% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1.47 | 0.60 | -59.21% |
| P/S Multiple | 8.13 | 5.86 | -27.92% |
| Shares Outstanding (Mil) | 1.31 | 1.77 | -35.04% |
| Cumulative Contribution | -80.90% |
Market Drivers
1/31/2025 to 1/16/2026| Return | Correlation | |
|---|---|---|
| LYRA | -78.2% | |
| Market (SPY) | 15.9% | -2.8% |
| Sector (XLV) | 7.4% | -2.9% |
Fundamental Drivers
The -98.6% change in LYRA stock from 1/31/2023 to 1/16/2026 was primarily driven by a -140.0% change in the company's Shares Outstanding (Mil).| 1312023 | 1162026 | Change | |
|---|---|---|---|
| Stock Price ($) | 142.50 | 1.99 | -98.60% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1.62 | 0.60 | -63.03% |
| P/S Multiple | 64.67 | 5.86 | -90.93% |
| Shares Outstanding (Mil) | 0.74 | 1.77 | -140.02% |
| Cumulative Contribution | -101.34% |
Market Drivers
1/31/2023 to 1/16/2026| Return | Correlation | |
|---|---|---|
| LYRA | -98.6% | |
| Market (SPY) | 76.5% | -1.9% |
| Sector (XLV) | 22.2% | -1.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| LYRA Return | -62% | -28% | 67% | -96% | -70% | -37% | -100% |
| Peers Return | 4% | -5% | 5% | -6% | 7% | 2% | 6% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| LYRA Win Rate | 33% | 33% | 58% | 33% | 25% | 0% | |
| Peers Win Rate | 52% | 52% | 55% | 50% | 57% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| LYRA Max Drawdown | -63% | -44% | -38% | -97% | -99% | -39% | |
| Peers Max Drawdown | -12% | -23% | -14% | -13% | -18% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | 0% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, SYK, JNJ, REGN, ANIK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/16/2026 (YTD)
How Low Can It Go
| Event | LYRA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -87.5% | -25.4% |
| % Gain to Breakeven | 700.5% | 34.1% |
| Time to Breakeven | 812 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -50.0% | -33.9% |
| % Gain to Breakeven | 100.0% | 51.3% |
| Time to Breakeven | 1,636 days | 148 days |
Compare to MDT, SYK, JNJ, REGN, ANIK
In The Past
Lyra Therapeutics's stock fell -87.5% during the 2022 Inflation Shock from a high on 3/1/2021. A -87.5% loss requires a 700.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Lyra Therapeutics:
- Alcon for ENT conditions: Alcon is known for specialized drugs and devices for eye care; Lyra Therapeutics focuses on similar specialized solutions for ear, nose, and throat (ENT) diseases.
- Medtronic for drug-eluting sinus implants: Medtronic is a leading medical device company with drug-eluting products; Lyra Therapeutics specializes in drug-eluting implants specifically for chronic sinus issues.
- Nasonex, but delivered via a long-lasting implant: Nasonex (mometasone furoate) is a well-known nasal spray for sinusitis; Lyra Therapeutics uses the same active ingredient but delivers it through an innovative, long-lasting absorbable implant directly to the sinus passages.
AI Analysis | Feedback
- LYR-210: An investigational drug candidate for chronic rhinosinusitis (CRS), designed as a bioresorbable drug matrix for local delivery of mometasone furoate to non-surgical patients.
- LYR-220: An investigational drug candidate for chronic rhinosinusitis (CRS), designed as a bioresorbable drug matrix for local delivery of mometasone furoate to patients who have undergone sinus surgery.
AI Analysis | Feedback
```htmlLyra Therapeutics (LYRA) is a clinical-stage biotechnology company focused on developing novel treatments for chronic rhinosinusitis (CRS). As of now, their product candidates (LYR-210 and LYR-220) are in clinical trials and have not yet received regulatory approval for commercialization.
Therefore, Lyra Therapeutics does not currently have major customers in the traditional sense of selling commercial products or services to individuals or other companies. Their primary activities involve research, development, and conducting clinical trials for their investigational therapies. Revenue, if any, typically comes from financing activities, grants, or potential future collaboration agreements, rather than product sales to end-users or distributors.
```AI Analysis | Feedback
nullAI Analysis | Feedback
Maria Palasis, Ph.D. President and Chief Executive Officer
Dr. Palasis has served as Lyra Therapeutics' President and Chief Executive Officer and a member of its board of directors since January 2015. She is an accomplished scientist, inventor, entrepreneur, and healthcare industry leader with nearly 25 years of experience. Prior to Lyra Therapeutics, Dr. Palasis was President and CEO of both Arsenal Medical and its spin-out, 480 Biomedical. At these companies, she secured strategic partnerships with large medical device companies and led multiple programs from pre-clinical into clinical development. She also previously managed a portfolio of external biotech and medical device investments at Boston Scientific Corporation, where she was involved in the development of the TAXUSâ„¢ drug-eluting stent. Dr. Palasis has led the raising of over $300 million in private and public proceeds from investors and non-dilutive government and strategic funding. She is an inventor on over 120 issued and pending patents. In 2021, she was elected into the National Academy of Engineering for her contributions to medical devices and drug delivery systems.
Jason Cavalier Chief Financial Officer
Jason Cavalier was appointed Chief Financial Officer of Lyra Therapeutics in September 2021. He brings over two decades of investment banking leadership experience with an extensive background in originating and executing financial transactions, particularly mergers and acquisitions. Most recently, he served as a Managing Director and the Head of Life Sciences Mergers and Acquisitions at Cantor Fitzgerald, where he led transactions across the medical technology, diagnostics, and biopharma sectors. Prior to Cantor Fitzgerald, Mr. Cavalier held senior-level positions at RBC Capital Markets, focusing on strategic advisory assignments and capital markets transactions, and also held investment banking roles at Barclays Capital, Bear Stearns, and Lehman Brothers.
Carmichael S. Roberts Jr., M.B.A., Ph.D. Co-Founder
Dr. Roberts is a co-founder of Lyra Therapeutics. He is also a co-founder of other companies, including Material Impact and Arsenal Medical, Inc. Lyra Therapeutics was formerly known as 480 Biomedical, Inc. and changed its name in July 2018.
Ronan P. O'Brien J.D. Chief Legal Officer
Ronan O'Brien has over 25 years of legal experience and is skilled at building and operating in-house legal functions. He served as General Counsel, Chief Compliance Officer & Secretary of Pear Therapeutics, Inc. from 2018 to 2023. Before Pear, Mr. O'Brien held leadership roles at other clinical-stage biotech companies, including Selecta Biosciences, Inc. and Cerulean Pharma, Inc.
Jeffrey Carbeck Co-Founder and Chief Technology Officer
Jeffrey Carbeck is a co-founder and Chief Technology Officer at Lyra Therapeutics Inc.
AI Analysis | Feedback
Key Risks to Lyra Therapeutics (LYRA)
- Financial Challenges and Need for Additional Funding: Lyra Therapeutics has a history of significant operating losses and dwindling cash reserves, raising concerns about its ability to continue as a going concern. The company reported a net loss of $5.98 million in Q3 2025, and its cash reserves fell to $22.1 million from $40.6 million. Despite cost-cutting measures, including workforce reductions and subleasing properties, Lyra's cash runway is projected to extend only into the third quarter of 2026, necessitating additional capital to fund ongoing operations and future clinical trials.
- Clinical Trial Outcomes and Regulatory Uncertainty: The failure of the ENLIGHTEN 1 Phase 3 trial for its lead product candidate, LYR-210, was a significant setback. While the ENLIGHTEN 2 trial met its primary endpoint, the U.S. Food and Drug Administration (FDA) is requiring a new confirmatory Phase 3 clinical trial to support a New Drug Application (NDA). This prolongs the development timeline, increases costs, and introduces further uncertainty regarding regulatory approval and potential commercialization, as the company is heavily reliant on the success of LYR-210.
- Manufacturing and Commercialization Risks: Lyra Therapeutics is in the process of transitioning its manufacturing for LYR-210 from a contract manufacturing organization to an in-house facility, and it has not yet established commercial manufacturing capabilities. This transition, combined with recent reductions in experienced personnel, presents risks of production delays, potential lot failures, and challenges in meeting regulatory requirements. The company has also halted manufacturing and commercialization efforts for its LYR-220 project to conserve capital.
AI Analysis | Feedback
The increasing market penetration and efficacy of biologic therapies, such as dupilumab (Dupixent) and omalizumab (Xolair), for chronic rhinosinusitis with nasal polyps pose a clear emerging threat. These systemic treatments target the underlying Type 2 inflammation that drives a significant portion of chronic rhinosinusitis, potentially reducing the addressable market and value proposition for Lyra Therapeutics' localized corticosteroid delivery systems, particularly in patients with more severe disease.
AI Analysis | Feedback
Lyra Therapeutics focuses on developing treatments for Chronic Rhinosinusitis (CRS), with its main product candidates being LYR-210 and LYR-220.
The company's therapies are designed to address an estimated four million CRS patients in the United States who do not respond to medical management each year.
- LYR-210: This product candidate targets CRS patients, both with and without nasal polyps, who have not had previous ethmoid sinus surgery and have failed conventional medical management. The addressable market for LYR-210 is estimated to be 2.4 million patients annually in the U.S.
- LYR-220: This product candidate is intended for post-surgical CRS patients who continue to experience symptoms despite having undergone sinus surgery. The estimated addressable market for LYR-220 is 1.6 million patients annually in the U.S. Notably, there is currently no FDA-approved product to treat post-surgery CRS patients without polyps, which represents the majority of these patients.
For broader context, the global Chronic Rhinosinusitis market was valued at approximately USD 10.2 billion in 2024 and is projected to reach USD 19.4 billion by 2034. North America accounted for about 40% of the global CRS market in 2024, with a value of USD 4.1 billion.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Lyra Therapeutics (symbol: LYRA) over the next 2-3 years:
- Commercialization of LYR-210 for Chronic Rhinosinusitis (CRS) without Nasal Polyps: Lyra Therapeutics achieved positive Phase 3 ENLIGHTEN 2 trial results for LYR-210 in June 2025, demonstrating a statistically significant improvement in cardinal symptoms for CRS patients without nasal polyps. This success is actively driving manufacturing and regulatory strategy to advance LYR-210 as a potential six-month treatment for millions of patients unresponsive to standard CRS medical management. The company is currently analyzing the comprehensive dataset from both the ENLIGHTEN 1 and ENLIGHTEN 2 trials to define the optimal path forward for LYR-210.
- Potential Market Expansion with LYR-220 for CRS Patients with Prior Ethmoid Sinus Surgery (ESS): LYR-220, a larger nasal insert, is specifically designed for CRS patients who have undergone previous ethmoid sinus surgery and have an enlarged nasal cavity. In September 2023, Lyra Therapeutics announced positive topline results from the BEACON Phase 2 clinical trial for LYR-220, which showed statistically significant and clinically relevant improvements in both the Sino-Nasal Outcome Test (SNOT-22) score and a composite of the three cardinal symptoms of CRS. The company has plans for an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for LYR-220 in the second half of 2024, indicating progress towards further development and potential future market entry.
- Advancement of LYR-210's Regulatory Pathway Leading to Potential Approval and Launch: The positive results from the ENLIGHTEN 2 Phase 3 trial are providing momentum for Lyra Therapeutics to optimize its regulatory strategy and resume manufacturing activities for LYR-210. Successful navigation of the regulatory process and subsequent approval by health authorities would be a direct catalyst for revenue generation through product sales of LYR-210.
AI Analysis | Feedback
Share Issuance
- Lyra Therapeutics may offer and sell up to $300,000,000 in aggregate of various securities through a shelf registration statement filed in March 2024.
- In June 2025, Lyra Therapeutics announced a registered direct offering and concurrent private placement aiming to raise up to approximately $15 million.
- The company's common stock issuances amounted to $8.8 million in 2024, $69.2 million in 2023, and $100.5 million in 2022.
Inbound Investments
- Lyra Therapeutics secured its largest funding round to date with a Post IPO round of $50 million in June 2023.
- The company has a collaboration agreement with LianBio Inflammatory Limited for the development and commercialization of LYR-210 in several Asian markets.
Capital Expenditures
- Capital expenditures were reported as -$13,000 over the last 12 months as of November 2025.
- Annual capital expenditures were -$2.3 million in 2024, -$1.0 million in 2023, and -$164,000 in 2022.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| Lyra Therapeutics Earnings Notes | ||
| Lyra Therapeutics Stock Rockets 56% With 6-Day Winning Streak | Notification | |
| With Lyra Therapeutics Stock Sliding, Have You Assessed The Risk? | Return |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Lyra Therapeutics
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 157.71 |
| Mkt Cap | 100.0 |
| Rev LTM | 19,314 |
| Op Inc LTM | 4,296 |
| FCF LTM | 3,977 |
| FCF 3Y Avg | 3,568 |
| CFO LTM | 4,952 |
| CFO 3Y Avg | 4,400 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | 2.7% |
| Rev Chg Q | 3.8% |
| QoQ Delta Rev Chg LTM | 0.9% |
| Op Mgn LTM | 19.5% |
| Op Mgn 3Y Avg | 19.0% |
| QoQ Delta Op Mgn LTM | -0.5% |
| CFO/Rev LTM | 20.1% |
| CFO/Rev 3Y Avg | 18.8% |
| FCF/Rev LTM | 15.8% |
| FCF/Rev 3Y Avg | 14.8% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases | 2 | 1 | |||
| Total | 2 | 1 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases | -67 | ||||
| Total | -67 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases | -63 | ||||
| Total | -63 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases | 55 | 81 | 15 | ||
| Total | 55 | 81 | 15 |
Price Behavior
| Market Price | $1.99 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 05/01/2020 | |
| Distance from 52W High | -92.8% | |
| 50 Days | 200 Days | |
| DMA Price | $3.60 | $6.53 |
| DMA Trend | down | down |
| Distance from DMA | -44.7% | -69.5% |
| 3M | 1YR | |
| Volatility | 123.7% | 4,931.8% |
| Downside Capture | 439.33 | 302.57 |
| Upside Capture | -312.37 | 97.43 |
| Correlation (SPY) | 17.6% | -2.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.66 | 2.48 | 2.20 | 1.97 | -6.87 | -3.56 |
| Up Beta | -8.54 | -1.18 | -1.77 | -0.29 | -0.26 | 0.24 |
| Down Beta | 4.29 | 4.25 | 2.46 | 2.35 | 11.38 | 4.44 |
| Up Capture | 171% | -11% | 75% | 50% | 176% | -3% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 9 | 14 | 23 | 50 | 97 | 332 |
| Down Capture | 493% | 406% | 365% | 296% | 162% | 109% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 13 | 27 | 40 | 74 | 151 | 403 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| LYRA vs. Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| LYRA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -79.0% | 12.7% | 19.8% | 70.5% | 3.8% | 10.2% | -1.2% |
| Annualized Volatility | 4,912.2% | 17.3% | 19.3% | 20.0% | 15.3% | 16.7% | 34.5% |
| Sharpe Ratio | 0.99 | 0.53 | 0.81 | 2.56 | 0.04 | 0.41 | 0.06 |
| Correlation With Other Assets | -2.9% | -2.8% | -1.6% | -1.5% | -0.4% | -2.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| LYRA vs. Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| LYRA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -67.3% | 7.4% | 14.1% | 19.4% | 11.1% | 6.1% | 20.0% |
| Annualized Volatility | 2,198.3% | 14.5% | 17.1% | 15.6% | 18.7% | 18.8% | 48.1% |
| Sharpe Ratio | 0.43 | 0.34 | 0.66 | 1.00 | 0.47 | 0.23 | 0.45 |
| Correlation With Other Assets | -1.3% | -1.1% | -0.5% | -0.4% | 0.1% | -0.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| LYRA vs. Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| LYRA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -66.0% | 10.5% | 15.5% | 14.8% | 7.6% | 5.9% | 70.8% |
| Annualized Volatility | 2,060.8% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.7% |
| Sharpe Ratio | 0.40 | 0.52 | 0.75 | 0.83 | 0.35 | 0.25 | 0.91 |
| Correlation With Other Assets | -1.2% | -1.0% | -0.5% | -0.4% | 0.1% | -0.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/12/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/06/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 03/13/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/12/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 08/14/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 04/30/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 03/22/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 11/07/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/08/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/12/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 03/29/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/08/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 08/09/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 05/10/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 03/09/2022 | 10-K (12/31/2021) |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.